LBA3 Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial

J Li,S Cang,Y Ling,K.O Lam,Y Chen,Y Xu,Y Yang,G Lavy-Shahaf,J Zhang

doi:10.1016/j.annonc.2022.10.101

LBA3 Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial

J Li, S Cang + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.101

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Shanghai East Hospital, Henan Provincial People's Hospital, Hangzhou Cancer Hospital, University of Hong Kong, First Affiliated Hospital of Henan University of Science and Technology, Shanghai Jiao Tong University

#Gastroesophageal Junction Adenocarcinoma #Gastric Cancer Cells + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tumor Treating Fields (TTFields) therapy is a locoregional, noninvasive treatment approved for glioblastoma and mesothelioma. TTFields, electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, are generated by a portable device, delivered by skin-placed arrays. In vitro data show synergistic cytotoxic effects with TTFields and chemotherapy in gastric cancer cells, warranting clinical investigation of TTFields therapy concomitant with chemotherapy in GC/GEJC.

Full Text